FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114264989> ?p ?o ?g. }

• W2114264989 endingPage "3630" @default.
• W2114264989 startingPage "3623" @default.
• W2114264989 abstract "Purpose We investigated disease-free survival (DFS) and overall survival (OS) after response-guided neoadjuvant chemotherapy in patients with early breast cancer. Patients and Methods We treated 2,072 patients with two cycles of docetaxel, doxorubicin, and cyclophosphamide (TAC) and randomly assigned early responders to four (n = 704) or six (n = 686) additional TAC cycles, and early nonresponders to four cycles of TAC (n = 321) or vinorelbine and capecitabine (NX; n = 301) before surgery. Results DFS was longer in early responders receiving TAC × 8 than in those receiving TAC × 6 (hazard ratio [HR], 0.78; 95% CI, 0.62 to 0.97; P = .026), and in early nonresponders receiving TAC-NX than in those receiving TAC × 6 (HR, 0.59; 95% CI, 0.49 to 0.82; P = .001). Exploratory analysis showed that DFS after response-guided chemotherapy (TAC × 8 or TAC-NX) was significantly longer (HR, 0.71; 95% CI, 0.60 to 0.85; P < .003), as was OS (HR, 0.79; 95% CI, 0.63 to 0.99; P = .048), than on conventional chemotherapy (TAC × 6). DFS was longer after response-guided chemotherapy in all hormone receptor–positive tumors (luminal A HR = 0.55, luminal B [human epidermal growth factor receptor 2 (HER2) negative] HR = 0.40, and luminal B [HER2 positive] HR = 0.56), but not in hormone receptor–negative tumors (HER2 positive [nonluminal] HR = 1.01 and triple negative HR = 0.87). Pathologic complete response did not predict these survival effects. pCR predicted an improved DFS in triple-negative (HR = 6.67), HER2-positive (nonluminal; HR 5.24), or luminal B (HER2-negative) tumors (HR = 3.74). Conclusion This exploratory analysis suggests that response-guided neoadjuvant chemotherapy might improve survival and is most effective in hormone receptor–positive tumors. If confirmed, the response-guided approach could provide a clinically meaningful advantage for the neoadjuvant over the adjuvant approach in early breast cancer." @default.
• W2114264989 created "2016-06-24" @default.
• W2114264989 creator A5002412211 @default.
• W2114264989 creator A5003405177 @default.
• W2114264989 creator A5004942036 @default.
• W2114264989 creator A5011410319 @default.
• W2114264989 creator A5014934109 @default.
• W2114264989 creator A5016987068 @default.
• W2114264989 creator A5024469109 @default.
• W2114264989 creator A5024741688 @default.
• W2114264989 creator A5033698551 @default.
• W2114264989 creator A5035387502 @default.
• W2114264989 creator A5056688392 @default.
• W2114264989 creator A5056873538 @default.
• W2114264989 creator A5065729408 @default.
• W2114264989 creator A5067146231 @default.
• W2114264989 creator A5069170386 @default.
• W2114264989 creator A5070416057 @default.
• W2114264989 creator A5071658752 @default.
• W2114264989 creator A5087559224 @default.
• W2114264989 creator A5089392438 @default.
• W2114264989 date "2013-10-10" @default.
• W2114264989 modified "2023-10-12" @default.
• W2114264989 title "Response-Guided Neoadjuvant Chemotherapy for Breast Cancer" @default.
• W2114264989 cites W2015159040 @default.
• W2114264989 cites W2024298772 @default.
• W2114264989 cites W2055679225 @default.
• W2114264989 cites W2076139950 @default.
• W2114264989 cites W2078667073 @default.
• W2114264989 cites W2087179076 @default.
• W2114264989 cites W2096864872 @default.
• W2114264989 cites W2098333537 @default.
• W2114264989 cites W2109079833 @default.
• W2114264989 cites W2124623816 @default.
• W2114264989 cites W2127267391 @default.
• W2114264989 cites W2135378470 @default.
• W2114264989 cites W2138613537 @default.
• W2114264989 cites W2140654333 @default.
• W2114264989 cites W2143399650 @default.
• W2114264989 cites W2147415463 @default.
• W2114264989 cites W2150706560 @default.
• W2114264989 cites W2163403096 @default.
• W2114264989 cites W4233358210 @default.
• W2114264989 cites W93096170 @default.
• W2114264989 doi "https://doi.org/10.1200/jco.2012.45.0940" @default.
• W2114264989 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24002511" @default.
• W2114264989 hasPublicationYear "2013" @default.
• W2114264989 type Work @default.
• W2114264989 sameAs 2114264989 @default.
• W2114264989 citedByCount "287" @default.
• W2114264989 countsByYear W21142649892013 @default.
• W2114264989 countsByYear W21142649892014 @default.
• W2114264989 countsByYear W21142649892015 @default.
• W2114264989 countsByYear W21142649892016 @default.
• W2114264989 countsByYear W21142649892017 @default.
• W2114264989 countsByYear W21142649892018 @default.
• W2114264989 countsByYear W21142649892019 @default.
• W2114264989 countsByYear W21142649892020 @default.
• W2114264989 countsByYear W21142649892021 @default.
• W2114264989 countsByYear W21142649892022 @default.
• W2114264989 countsByYear W21142649892023 @default.
• W2114264989 crossrefType "journal-article" @default.
• W2114264989 hasAuthorship W2114264989A5002412211 @default.
• W2114264989 hasAuthorship W2114264989A5003405177 @default.
• W2114264989 hasAuthorship W2114264989A5004942036 @default.
• W2114264989 hasAuthorship W2114264989A5011410319 @default.
• W2114264989 hasAuthorship W2114264989A5014934109 @default.
• W2114264989 hasAuthorship W2114264989A5016987068 @default.
• W2114264989 hasAuthorship W2114264989A5024469109 @default.
• W2114264989 hasAuthorship W2114264989A5024741688 @default.
• W2114264989 hasAuthorship W2114264989A5033698551 @default.
• W2114264989 hasAuthorship W2114264989A5035387502 @default.
• W2114264989 hasAuthorship W2114264989A5056688392 @default.
• W2114264989 hasAuthorship W2114264989A5056873538 @default.
• W2114264989 hasAuthorship W2114264989A5065729408 @default.
• W2114264989 hasAuthorship W2114264989A5067146231 @default.
• W2114264989 hasAuthorship W2114264989A5069170386 @default.
• W2114264989 hasAuthorship W2114264989A5070416057 @default.
• W2114264989 hasAuthorship W2114264989A5071658752 @default.
• W2114264989 hasAuthorship W2114264989A5087559224 @default.
• W2114264989 hasAuthorship W2114264989A5089392438 @default.
• W2114264989 hasBestOaLocation W21142649891 @default.
• W2114264989 hasConcept C121608353 @default.
• W2114264989 hasConcept C126322002 @default.
• W2114264989 hasConcept C143998085 @default.
• W2114264989 hasConcept C207103383 @default.
• W2114264989 hasConcept C2776694085 @default.
• W2114264989 hasConcept C2776755627 @default.
• W2114264989 hasConcept C2777909004 @default.
• W2114264989 hasConcept C2778239845 @default.
• W2114264989 hasConcept C2780110267 @default.
• W2114264989 hasConcept C2780350996 @default.
• W2114264989 hasConcept C2781190966 @default.
• W2114264989 hasConcept C44249647 @default.
• W2114264989 hasConcept C526805850 @default.
• W2114264989 hasConcept C530470458 @default.
• W2114264989 hasConcept C71924100 @default.
• W2114264989 hasConcept C90924648 @default.

• next